Strategies for the development of new PPAR agonists in diabetes.
Diabetes is associated with a range of metabolic abnormalities including insulin resistance, atherogenic dyslipidemia, hypertension, and inflammation. These factors are likely to underlie the adverse cardiovascular outcome typically observed in diabetic cohorts. The family of peroxisome proliferator-activated receptors (PPARs) have been implicated in the regulation of a number of physiologic and metabolic pathways. Pharmacologic agonists directed against various PPARs have been shown to have a beneficial impact on these metabolic risk factors. The potential impact on cardiovascular risk with the use of PPAR agonists will be reviewed.
Cavender
Matthew A
MA
Department of Cardiovascular Medicine, The Cleveland Clinic, Cleveland, Ohio 44195, USA. matt.cavender@gmail.com
Nicholls
Stephen J
SJ
Lincoff
A Michael
AM
D000818:Animals; D001786:Blood Glucose / Q000187:drug effects; D002318:Cardiovascular Diseases / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control*; D048909:Diabetes Complications / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control*; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000378:metabolism; D015195:Drug Design; D006801:Humans; D007004:Hypoglycemic Agents / Q000737:chemistry / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D047492:Peroxisome Proliferator-Activated Receptors / Q000819:agonists* / Q000378:metabolism; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D008055:Lipids; D047492:Peroxisome Proliferator-Activated Receptors